German pharmaceutical company Life Molecular Imaging Ltd (LMI) announced on Tuesday that the US Food and Drug Administration (FDA) has approved updated labelling for Neuraceq (florbeteben F18 injection), expanding its indication for selecting patients for amyloid-targeting therapies, as described in the prescribing information of the therapeutic products, and including the utilisation of quantitative analysis for positron emission tomography (PET) scans.
Key updates to the Neuraceq label include: expanded clinical indication to include use in both diagnostic assessment and identification of appropriate candidates for FDA-approved amyloid-targeting therapies; utilisation of quantitative amyloid plaque metrics in conjunction with visual image interpretation; and broader use for monitoring of therapy and following progression to Alzheimer's disease (AD).
The safety profile of Neuraceq has been confirmed to remain unchanged with the new indication.
Neuraceq is indicated for PET of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for evaluation of AD and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
GSK announces submission of RSV vaccine Arexvy for FDA review
Imugene announces Azer-cel Phase 1b clinical trial data
FDA approves Merck Animal Health's once-yearly flea and tick treatment for dogs
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials